News
- Author:
- Mary Jo M. Dales
Publish date: May 3, 2018
Next-generation sequencing results might prove useful for guiding targeted therapy that could improve the treatment outcomes of patients with advan...
News
- Author:
- Mary Jo M. Dales
Publish date: October 6, 2017
The cobas Zika test is the first test approved for screening the blood supply.
News
- Author:
- Mary Jo M. Dales
Publish date: August 7, 2017
Vemurafenib (Zelboraf) has been granted a supplemental new drug application and priority review by the Food and Drug Administration for the treatme...
News
- Author:
- Mary Jo M. Dales
Publish date: August 3, 2017
Vyxeos, a liposome-encapsulated combination of daunorubicin and cytarabine, has been approved for the treatment of adults with newly-diagnosed ther...
News
- Author:
- Mary Jo M. Dales
Publish date: August 2, 2017
Ibrutinib (Imbruvica) added another notch on its indications belt with its August 2 approval by the U.S. Food and Drug Administration for the treat...
News
- Author:
- Mary Jo M. Dales
Publish date: August 1, 2017
“Idhifa is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH2 mutation,” said Richard Pazdur...
News
- Author:
- Mary Jo M. Dales
Publish date: July 27, 2017
Starting patients on a reduced dose and increasing it gradually while monitoring carefully for adverse events, meant patients did not have to stop ...
News
- Author:
- Mary Jo M. Dales
Publish date: July 26, 2017
FLT3-ligand (FLT3-L) levels exceeding 92 pg/mL in bone marrow and 121 pg/mL in peripheral blood are associated with relapsed and refractory disease...
News
- Author:
- Mary Jo M. Dales
Publish date: June 23, 2017
CHICAGO – A treatment for acute myeloid leukemia may be derived from the immortalized B cells of an AML patient who was cured after allogeneic stem...
News
- Author:
- Mary Jo M. Dales
Publish date: June 22, 2017
CHICAGO – Lenalidomide consolidation therapy was associated with an extended survival plateau for patients with non-del(11q) chronic lymphocytic le...
News
- Author:
- Mary Jo M. Dales
Publish date: June 22, 2017
CHICAGO – Bendamustine plus rituximab may have some advantages for treatment-naive patients with indolent non-Hodgkin lymphoma or mantle cell lymph...
News
- Author:
- Mary Jo M. Dales
Publish date: June 3, 2017
CHICAGO – Certain types of severe morbidity have steadily declined in childhood cancer survivors.
Video
- Author:
- Mary Jo M. Dales
Publish date: June 3, 2017
Steady improvements seen in participants in the Childhood Cancer Survivor Study.
News
- Author:
- Mary Jo M. Dales
Publish date: May 20, 2017
High-risk patients with mantle cell lymphoma who have a matched related donor have a better chance for survival if they do not delay allogeneic hem...
News
- Author:
- Mary Jo M. Dales
Publish date: May 19, 2017
The peripheral blood absolute lymphocyte-to-monocyte ratio (ALC/AMC) was prognostic for overall survival in mantle cell lymphoma patients who have ...
